SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001069530-20-000045
Filing Date
2020-08-12
Accepted
2020-08-12 17:08:23
Documents
43
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q sava-20200630x10q.htm 10-Q 832909
2 EX-31.1 sava-20200630xex31_1.htm EX-31.1 25504
3 EX-31.2 sava-20200630xex31_2.htm EX-31.2 25203
4 EX-32.1 sava-20200630xex32_1.htm EX-32.1 20318
  Complete submission text file 0001069530-20-000045.txt   3298986

Data Files

Seq Description Document Type Size
5 EX-101.INS sava-20200630.xml EX-101.INS 690741
6 EX-101.SCH sava-20200630.xsd EX-101.SCH 23794
7 EX-101.CAL sava-20200630_cal.xml EX-101.CAL 23514
8 EX-101.DEF sava-20200630_def.xml EX-101.DEF 58756
9 EX-101.LAB sava-20200630_lab.xml EX-101.LAB 181430
10 EX-101.PRE sava-20200630_pre.xml EX-101.PRE 151305
Mailing Address 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260 AUSTIN TX 78731
Business Address 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260 AUSTIN TX 78731 512-501-2444
CASSAVA SCIENCES INC (Filer) CIK: 0001069530 (see all company filings)

IRS No.: 911911336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-29959 | Film No.: 201096148
SIC: 2834 Pharmaceutical Preparations